Session: New treatments for hereditary ovarian cancer

Speaker: Elise Kohn, MD

This 90-minute concurrent session will focus on information on PARP Inhibitors.
Dr. Kohn will discuss:

• PARP Inhibitors; as targeted therapy for ovarian cancer associated with BRCA
• available PARP Inhibitor studies
• inclusion and exclusion criteria for PARP Inhibitor studies
• updates on PARP Inhibitor effectiveness, and/or resistance in particular patients
• other potential targeted therapy for hereditary ovarian cancers
  

This session is appropriate for:

• ovarian, and other cancer survivors
• parents/relatives/loved ones of breast, ovarian, and other cancer survivors
• health care providers who provide care to people with breast, ovarian, and other hereditary cancers
• social workers/mental health care professionals who treat people with breast, ovarian and other
  hereditary cancers
  

Close Window